Evidence map›Paper›PMID 28431584›Full record

ArticleHarm reduction journal2017

Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study.

Lucas Wiessing, Marica Ferri, Vendula Běláčková, Patrizia Carrieri, Samuel R Friedman, Cinta Folch, Kate Dolan, Brian Galvin, Peter Vickerman, Jeffrey V Lazarus and 22 more

Open access · goldAbstract readConsensus Statement
In one paragraph

Article in Harm reduction journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. People who use drugs and the right to health.Harm reduction journal · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 15 institutions in 15 countries.

Lucas WiessingEuropean Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Praça Europa 1, Cais do Sodré, 1249-289, Lisbon, Portugal. Lucas.Wiessing@emcdda.europa.eu.ORCID 0000-0002-2078-2826
Marica FerriEuropean Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Praça Europa 1, Cais do Sodré, 1249-289, Lisbon, Portugal.
Vendula BěláčkováDepartment of Addictology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Patrizia CarrieriMarseille Univ, INSERM, IRD, SESSTIM, Marseille, France.
Samuel R FriedmanInstitute of Infectious Disease Research, National Development and Research Institutes, New York, USA.
Cinta FolchCentre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Agència de Salut Pública de Catalunya (ASPC), Barcelona, Spain.
Kate DolanProgram of International Research and Training, National Drug and Alcohol Research Centre, The University of New South Wales (UNSW), Sydney, Australia.
Brian GalvinHealth Research Board, Dublin, Ireland.
Peter VickermanSchool of Social and Community Medicine, University of Bristol, Bristol, UK.
Jeffrey V LazarusCHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Viktor MravčíkDepartment of Addictology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Mirjam KretzschmarJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Vana SypsaDepartment of Hygiene Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Ana Sarasa-RenedoConsortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Anneli UuskülaDepartment of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
Dimitrios ParaskevisDepartment of Hygiene Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Luis MendãoGroup of Activists on Treatments (GAT), Lisbon, Portugal.
Diana RossiIntercambios Civil Association and University of Buenos Aires, Buenos Aires, Argentina.
Nadine van GelderEuropean Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Praça Europa 1, Cais do Sodré, 1249-289, Lisbon, Portugal.
Luke MitchesonAlcohol, Drug, and Tobacco Division, Health and Wellbeing Directorate, Public Health England, London, UK.
Letizia PaoliLeuven Institute of Criminology (LINC), Faculty of Law, University of Leuven, Leuven, Belgium.
Cristina Diaz GomezFrench Monitoring Centre for Drugs and Drug Addiction (OFDT), Saint-Denis, France.
Maitena MilhetFrench Monitoring Centre for Drugs and Drug Addiction (OFDT), Saint-Denis, France.
Nicoleta DascaluThe Romanian Association Against AIDS (ARAS), Bucharest, Romania.
Jonathan KnightDepartment of Health, Wellington House, London, UK.
Gordon HayPublic Health Institute, Faculty of Education, Health and Community, Liverpool John Moores University, Liverpool, UK.
Eleni KalamaraEuropean Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Praça Europa 1, Cais do Sodré, 1249-289, Lisbon, Portugal.
Roland SimonEuropean Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Praça Europa 1, Cais do Sodré, 1249-289, Lisbon, Portugal.
EUBEST working group
Catherine ComiskeyTrinity College Dublin, The University of Dublin, Dublin, Ireland.
Carla RossiCentro Studi Statistici e Sociali CE3S, Rome, Italy.
Paul GriffithsEuropean Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Praça Europa 1, Cais do Sodré, 1249-289, Lisbon, Portugal.
European Monitoring Centre for Drugs and Drug Addiction · PTNational and Kapodistrian University of Athens · GRCharles University · CZNational Development and Research Institutes · USRomanian Space Agency · ROTrinity College Dublin · IEUniversidad de Buenos Aires · ARUniversity of Copenhagen · DKUNSW Sydney · AUEuropean Corporate Governance Institute · BEInserm · FRInstituto de Salud Carlos III · ESLiverpool John Moores University · GBPublic Health England · GBUniversity of Bristol · GB

Funding

Transdisciplinary Theoretical Svnthesis and Development CoreP30DA011041 · NIDA · NEW YORK UNIVERSITY · PI Holly Hagan, Courtney McKnight · 1998 to 2026
$38.9M
COMMUNITY VULNERABILITY AND RESPONSES TO IDU-RELATED HIVR01DA013336 · NIDA · NATIONAL DEVELOPMENT &RES INSTITUTES · PI COOPER, HANNAH LF, FRIEDMAN, SAMUEL R · 2000 to 2013
$7.6M
Preventing HIV Transmission by Recently-Infected Drug UsersDP1DA034989 · NIDA · NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES, INC. · PI FRIEDMAN, SAMUEL R · 2012 to 2016
$3.8M
NIDA NIH HHS DP1 DA034989NIDA NIH HHS P30 DA011041NIDA NIH HHS R01 DA013336
6 · The paper itself

Abstract

BACKGROUND AND

aimsDespite advances in our knowledge of effective services for people who use drugs over the last decades globally, coverage remains poor in most countries, while quality is often unknown. This paper aims to discuss the historical development of successful epidemiological indicators and to present a framework for extending them with additional indicators of coverage and quality of harm reduction services, for monitoring and evaluation at international, national or subnational levels. The ultimate aim is to improve these services in order to reduce health and social problems among people who use drugs, such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection, crime and legal problems, overdose (death) and other morbidity and mortality. METHODS AND

resultsThe framework was developed collaboratively using consensus methods involving nominal group meetings, review of existing quality standards, repeated email commenting rounds and qualitative analysis of opinions/experiences from a broad range of professionals/experts, including members of civil society and organisations representing people who use drugs. Twelve priority candidate indicators are proposed for opioid agonist therapy (OAT), needle and syringe programmes (NSP) and generic cross-cutting aspects of harm reduction (and potentially other drug) services. Under the specific OAT indicators, priority indicators included 'coverage', 'waiting list time', 'dosage' and 'availability in prisons'. For the specific NSP indicators, the priority indicators included 'coverage', 'number of needles/syringes distributed/collected', 'provision of other drug use paraphernalia' and 'availability in prisons'. Among the generic or cross-cutting indicators the priority indicators were 'infectious diseases counselling and care', 'take away naloxone', 'information on safe use/sex' and 'condoms'. We discuss conditions for the successful development of the suggested indicators and constraints (e.g. funding, ideology). We propose conducting a pilot study to test the feasibility and applicability of the proposed indicators before their scaling up and routine implementation, to evaluate their effectiveness in comparing service coverage and quality across countries.

conclusionsThe establishment of an improved set of validated and internationally agreed upon best practice indicators for monitoring harm reduction service will provide a structural basis for public health and epidemiological studies and support evidence and human rights-based health policies, services and interventions.

Indexed as

Harm ReductionQuality of Health CareConsensusHumansSubstance-Related DisordersBest practiceCoverageDrug servicesEpidemiologyEvidence-basedHarm reductionHCVHIVIndicatorsInjecting drug users/IDUInterventionsKnowledge exchangeMonitoringPeople who inject drugs/PWIDPeople who use drugs/PWUDSubstance abuse

Identifiers

PMID28431584
PMCPMC5401609
OpenAlexW2606014799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.